Emerging drugs for the treatment of acromegaly. (1st October 2020)

• Record Type: Journal Article
• Authors: Campana, Claudia; Corica, Giuliana; Nista, Federica; Cocchiara, Francesco; Graziani, Giulia; Khorrami, Keyvan; Franco, Marta; Boschetti, Mara; Ferone, Diego; Gatto, Federico
• Is Part Of: Expert opinion on emerging drugs. Volume 25:Number 4(2020)
• Page Start: 409
• Page End: 417
• Publication Date: 2020-10-01
• Subjects: Acromegaly -- medical treatment -- somatostatin receptor ligands -- innovative treatments -- GH -- IGF-1; Drugs -- Research -- Handbooks, manuals, etc; Drugs -- Design -- Periodicals; 615.1072
• DOI: 10.1080/14728214.2020.1819983
• Languages: English
• ISSNs: 1472-8214

Abstract

ABSTRACT: Introduction: Acromegaly is a disease characterized by elevated growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels. Surgery is the only curative treatment, while medical therapies are administered life-long. To date, almost 30% of patients treated with the currently available medical therapies do not achieve biochemical control. Areas covered: This review focuses on new drugs in development for acromegaly. In detail, we provide an overview of the new molecules designed to improve disease control rate (such as novel somotostatin receptor ligands and antisense oligonucleotides), as well as the new formulations of existing medications aiming to improve patients' compliance (e.g. oral or long-acting subcutaneous octreotide). Expert opinion: The constant progresses in the medical treatment of acromegaly could lead to an individualized therapy based on tumor, as well as patient's characteristics. Besides disease control, patient's need represents a major target of medical treatment in chronic diseases such as acromegaly, in order to improve compliance to therapy and patients' quality of life.